Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum concentration–guided infliximab dosing versus standard dosing in severe sarcoidosis
2014-002224-26Phase 4Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in sarcoidosis (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: FVC at week 26. Started Feb 2015; status: active.
02
Drugs
infliximab
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on 2014-002224-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002224-26.